How the EMA Regulates Peptide Drugs in Europe

Peptide Regulation

80+ approved

Over 80 peptide therapeutics have received regulatory approval globally, with the EMA maintaining its own approval pathway that classifies synthetic peptides differently from biologics.

D'Aloisio et al., Drug Discovery Today, 2021

D'Aloisio et al., Drug Discovery Today, 2021

View as image

Peptide drugs sit in a regulatory gap between small molecules and biologics, and nowhere is that gap more consequential than in Europe. The European Medicines Agency (EMA) has spent decades developing frameworks for both chemical drugs and biological medicines, but synthetic peptides fit cleanly into neither category. They are too large and structurally complex for standard small-molecule guidelines, yet they are produced by chemical synthesis rather than biological systems, excluding them from the biosimilar pathway. Understanding how the EMA handles this classification directly affects which approval pathway a peptide drug follows, what quality data is required, and how follow-on products reach the European market. For broader regulatory context across jurisdictions, see Peptide Importation Laws and Peptide Regulation Around the World.

The EMA's centralized procedure

The EMA operates the centralized procedure, a single regulatory pathway that grants marketing authorization valid across all 27 EU member states simultaneously. This is the mandatory pathway for most peptide therapeutics because the centralized procedure is required for medicines derived from biotechnology processes, for orphan medicines, and for treatments of HIV/AIDS, cancer, diabetes, and neurodegenerative diseases. Most approved peptide drugs fall into at least one of these categories.^[1]

The Committee for Medicinal Products for Human Use (CHMP) evaluates applications submitted to the EMA and issues scientific opinions on whether a drug should be approved. Once the CHMP recommends approval, the European Commission issues a legally binding marketing authorization. The entire process typically takes 210 days of active assessment, though clock stops for applicant responses extend the real-world timeline to 12-15 months.

For peptide drugs specifically, the EMA requires the applicant to classify the product as either a chemical (synthetic) or biological (recombinant) medicine at the time of application. This classification determines which quality guidelines apply, which impurity standards must be met, and whether follow-on manufacturers can reference the original product through the generic, hybrid, or biosimilar pathway. The classification decision is made at the outset and cannot easily be changed later, making it one of the most consequential early regulatory decisions in European peptide drug development.^[2]

Alternative to the centralized procedure, some peptide drugs can be approved through national procedures (valid in one member state) or the mutual recognition procedure (extending a national approval to other member states). However, most novel peptide therapeutics use the centralized procedure because it provides a single pan-European authorization and is mandatory for several disease categories that peptide drugs commonly treat.

Synthetic vs. biological: the classification that matters

The EMA draws a critical regulatory distinction between peptides made by chemical synthesis and peptides made by recombinant DNA technology (expression in bacteria, yeast, or mammalian cells). This distinction has practical consequences.

Synthetic peptides (made by solid-phase or liquid-phase chemical synthesis) are classified as chemical medicines. Exenatide synthetic (Byetta), for example, is a 39-amino-acid GLP-1 receptor agonist produced by chemical synthesis and regulated as a chemical product. Synthetic peptides follow the chemical medicines quality framework, supplemented by the new EMA synthetic peptide guideline.

Recombinant peptides (produced using genetically engineered organisms) are classified as biological medicines. Semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) are GLP-1 receptor agonists produced by recombinant expression in yeast (Saccharomyces cerevisiae), making them biologics under EMA classification. Tirzepatide (Mounjaro/Zepbound) is produced in recombinant E. coli, also classifying it as a biologic.^[3]

This matters for follow-on products. When the patent on a biological peptide expires, competitors cannot file a standard generic application. They must file as biosimilars, demonstrating similarity in quality, safety, and efficacy through comparative studies. For synthetic peptides, competitors can file through the generic (Article 10.1) or hybrid (Article 10.3) pathway, which requires demonstrating pharmaceutical equivalence or similarity respectively. The generic pathway is faster and cheaper, but the hybrid pathway may be required when the follow-on product differs in route of administration, strength, or indication from the reference product.^[2]

The 2026 synthetic peptide guideline

In September 2022, the EMA's Quality Working Party published a draft guideline on the development and manufacture of synthetic peptides. After a public consultation period, the guideline was finalized in 2024 and takes effect in June 2026. It is the first EU-wide regulatory framework specifically addressing the quality requirements for synthetic peptide active substances.^[4]

The guideline exists because synthetic peptides fall outside the scope of several ICH guidelines that cover conventional small molecules. ICH Q3A and Q3B (impurities in drug substances and drug products) were designed for molecules under approximately 1,000 daltons. ICH Q6A and Q6B (specifications for chemical and biological substances) leave a gap for peptides of 2-50 amino acids. ICH M7 (mutagenic impurities) was not designed for the types of process-related impurities generated during solid-phase peptide synthesis.^[4]

Key requirements of the guideline

Impurity profiling. The guideline requires comprehensive characterization of peptide-related impurities including truncated sequences (where synthesis fails at a specific residue), deletion peptides (where a residue is skipped), epimerized sequences (where amino acid chirality is inverted), and oxidized variants. D'Hondt et al. (2014) documented 11 categories of process-related impurities in synthetic peptides and demonstrated that even low-level impurities (below 0.5%) can affect biological activity in functional assays.^[5]

Counter-ion control. Synthetic peptides typically contain counter-ions from the cleavage and purification process, most commonly trifluoroacetic acid (TFA) acetate. TFA is flagged by the EMA as a particular concern because of its environmental persistence and potential toxicity. The guideline requires justification of counter-ion identity and control of residual levels, with TFA requiring specific toxicological justification if present above specified limits.

Stability testing. Stress testing under conditions relevant to the peptide's intended storage and use, with stability-indicating analytical methods capable of resolving the active peptide from its degradation products. Peptides are inherently less stable than small molecules due to susceptibility to hydrolysis, oxidation, deamidation, and aggregation.^[1]

Starting materials. The guideline defines which synthetic intermediates qualify as regulatory starting materials for the active substance and requires appropriate controls on amino acid building blocks, coupling reagents, and resins used in solid-phase synthesis.

How EMA peptide regulation differs from FDA

The FDA and EMA share broad alignment on peptide drug evaluation through ICH harmonization, but several differences affect how peptides reach the European versus American market.

Classification. The FDA classifies all peptides as drugs regardless of manufacturing method. The EMA distinguishes between chemical and biological based on manufacturing process. A recombinant peptide that the FDA treats as a standard drug application may require a biologics-type application at the EMA, with different comparability requirements for manufacturing changes.^[6]

Follow-on products. The FDA has the 505(b)(2) pathway, which allows sponsors to reference published literature and the FDA's prior approval findings. The EMA's closest equivalent is the hybrid application (Article 10.3), but the evidentiary requirements differ. For recombinant peptides, the EMA's biosimilar pathway requires more extensive comparative clinical data than the FDA's, though a 2025 EMA draft proposal to reduce reliance on comparative efficacy trials may narrow this gap.

Compounding. In the US, compounding pharmacies can produce unapproved peptide preparations under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, subject to FDA oversight. European compounding (magistral or officinal preparation) operates under national pharmacy laws in each EU member state, with no centralized EMA oversight. This means compounded peptide availability and quality standards vary across Europe.

Post-approval changes. The EMA requires Type II variation applications for significant manufacturing changes to approved peptides (changes to synthesis route, purification process, or specification limits). The FDA handles comparable changes through Prior Approval Supplements. The practical timelines and data requirements differ, affecting how quickly manufacturers can implement process improvements.

Rastogi et al. (2019) reviewed the global regulatory landscape for peptide therapeutics and noted that the lack of peptide-specific ICH guidance has resulted in divergent regional approaches, with the EMA's 2026 guideline representing the first attempt by a major regulatory authority to create a comprehensive peptide-specific quality framework.^[2]

Approved peptide drugs in Europe: the current landscape

D'Aloisio et al. (2021) compiled the PepTherDia database cataloging all approved peptide therapeutics and diagnostics. Of the 80+ peptide drugs approved globally, the majority hold both FDA and EMA authorizations. Notable EMA-approved peptide drugs include:^[3]

GLP-1 receptor agonists: Semaglutide (Ozempic, 2018), liraglutide (Victoza, 2009), exenatide (Byetta, 2006), tirzepatide (Mounjaro, 2022). These represent the fastest-growing peptide drug class by revenue and prescriptions. The EMA addressed GLP-1 RA shortages in 2023-2024 through supply management recommendations.

Somatostatin analogs: Octreotide (Sandostatin, 1988) and lanreotide (Somatuline, 1994) for neuroendocrine tumors and acromegaly.

GnRH analogs: Leuprorelin (Eligard), goserelin (Zoladex), triptorelin (Decapeptyl) for prostate cancer, endometriosis, and precocious puberty.

Vasopressin analogs: Desmopressin (Minirin) for diabetes insipidus and nocturnal enuresis.

Zane et al. (2021) reviewed the development and regulatory challenges for peptide therapeutics and identified that the majority of approved peptides are administered by injection, which limits patient compliance. Oral peptide formulations (oral semaglutide, approved by the EMA as Rybelsus in 2020) represent a significant regulatory and pharmaceutical advance, requiring demonstration that the oral formulation achieves comparable bioavailability to the injectable version.^[6]

What this means for peptide access in Europe

European patients access approved peptide drugs through national healthcare systems, each with its own pricing, reimbursement, and formulary decisions. EMA approval does not guarantee patient access; it grants legal authorization to market the drug. National health technology assessment (HTA) bodies (NICE in the UK, G-BA in Germany, HAS in France) then evaluate cost-effectiveness before the drug becomes available through the public healthcare system.

For unapproved peptides (research peptides sold online, compounded preparations), European regulation is fragmented. Each EU member state regulates its own pharmacy compounding, online pharmacy rules, and importation enforcement. The EMA has no jurisdiction over research chemicals or compounded preparations. This creates a patchwork where a peptide legally available as a compounded preparation in one EU country may be prohibited in another.

Post-approval oversight and pharmacovigilance

The EMA's role does not end at approval. The Pharmacovigilance Risk Assessment Committee (PRAC) monitors safety signals for all approved medicines, including peptides, across the entire EU population. When safety concerns emerge, the PRAC can recommend label changes, risk management plan updates, or in extreme cases, marketing authorization suspension.

For peptide drugs, pharmacovigilance has been particularly active around GLP-1 receptor agonists. In 2023, the EMA's safety committee reviewed signals related to thyroid cancer and suicidal ideation associated with GLP-1 RAs, concluding that the evidence did not support a causal association for suicidal ideation but maintaining the existing thyroid monitoring recommendations. The EMA also addressed supply shortages of semaglutide and liraglutide beginning in 2023, issuing recommendations to manage demand and prevent off-label prescribing from depleting supplies for approved indications.^[3]

The EMA's Periodic Safety Update Report (PSUR) system requires marketing authorization holders to submit regular safety updates at defined intervals. For peptide drugs in their first two years post-approval, PSURs are typically required every six months. This continuous monitoring provides a safety net that pre-approval clinical trials, with their limited sample sizes and durations, cannot replicate.

Elsayed et al. (2025) reviewed the evolution of regulatory guidelines for peptide and protein analysis from the FDA and EMA since 1987, documenting how analytical requirements have become progressively more stringent as the approved peptide portfolio has expanded. The current framework reflects decades of accumulated knowledge about peptide-specific quality and safety risks that were not anticipated by the original small-molecule or biologic guidelines.^[1]

For more on the FDA's approach to peptide classification, see FDA Category 1 vs Category 2 Peptides. For the compounding pharmacy landscape, see How Compounding Pharmacies Make Peptides.

The Bottom Line

The EMA regulates peptide drugs through a classification system that distinguishes synthetic from recombinant peptides, determining whether follow-on products use the generic, hybrid, or biosimilar pathway. The 2026 synthetic peptide guideline fills a regulatory gap left by ICH guidelines designed for either small molecules or biologics, establishing specific quality requirements for impurity profiling, counter-ion control, and stability testing. European peptide regulation differs from the FDA's approach in classification, follow-on pathways, and compounding oversight.

Frequently Asked Questions

How does the EMA classify peptide drugs?

The EMA classifies peptide drugs based on their manufacturing method. Chemically synthesized peptides are regulated as chemical medicines. Peptides produced by recombinant DNA technology (in bacteria, yeast, or mammalian cells) are classified as biological medicines. This classification determines which quality guidelines apply and which pathway follow-on products must use. Semaglutide and liraglutide are classified as biologics because they are made in recombinant yeast, while exenatide synthetic is classified as a chemical medicine.

What is the EMA synthetic peptide guideline?

The EMA's Guideline on the Development and Manufacture of Synthetic Peptides was finalized in 2024 and takes effect in June 2026. It establishes the first EU-wide quality framework specific to synthetic peptides, covering impurity profiling (truncated sequences, deletion peptides, epimerized variants), counter-ion control (particularly TFA), stability testing requirements, and starting material definitions. It fills a gap left by ICH guidelines that were designed for small molecules or biologics but not peptides.

Can generic versions of peptide drugs be sold in Europe?

For chemically synthesized peptides, generic versions can be approved through the EMA's generic pathway (Article 10.1) by demonstrating pharmaceutical equivalence. For recombinant peptides classified as biologics, competitors must use the biosimilar pathway, which requires more extensive comparative quality, safety, and efficacy data. The hybrid pathway (Article 10.3) is used when the follow-on product differs from the reference product in route, strength, or indication.

How does EMA peptide regulation differ from FDA?

The main differences are: (1) the EMA distinguishes synthetic vs. recombinant peptides while the FDA treats all peptides as drugs regardless of manufacturing method; (2) the EMA's biosimilar pathway for recombinant peptides requires more comparative clinical data than the FDA's approach; (3) compounding in Europe falls under national pharmacy laws with no EMA oversight, while the FDA has centralized oversight of 503A and 503B compounding pharmacies.

What peptide impurities does the EMA specifically regulate?

The EMA's synthetic peptide guideline requires characterization of truncated sequences (synthesis failure at a specific residue), deletion peptides (skipped residues), epimerized sequences (inverted amino acid chirality), oxidized variants, and process-related impurities. Residual trifluoroacetic acid from peptide synthesis requires specific toxicological justification. D'Hondt et al. (2014) identified 11 categories of process-related impurities that can affect biological activity even at levels below 0.5%.

Is EMA approval the same as patient access in Europe?

No. EMA approval grants legal authorization to market a peptide drug across all 27 EU member states. However, patient access depends on national health technology assessment bodies (NICE in the UK, G-BA in Germany, HAS in France) that evaluate cost-effectiveness before adding drugs to public formularies. A drug can be EMA-approved but unavailable to patients in specific countries if the national HTA body determines it is not cost-effective at the proposed price.